Efficacy

Aliqopa (Copanlisib) Efficacy in Treating Lymphoma

Aliqopa (copanlisib) is a kinase inhibitor specifically designed for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. As a phosphatidylinositol-3-kinase (PI3K) inhibitor, Aliqopa disrupts cancer cell growth and survival. Its efficacy for this indication was demonstrated in a single-arm clinical trial, which assessed overall response rate (ORR) and duration of response (DOR) as primary endpoints. The results showed a significant proportion of patients achieving partial or complete response, indicating that Aliqopa can be an effective treatment option for this patient population.

The ORR observed in the pivotal study for Aliqopa was noteworthy, with many patients experiencing a reduction in tumor burden. The DOR was also clinically meaningful, with a subset of patients maintaining response for six months or longer. These findings suggest that Aliqopa can provide a durable response for some patients with relapsed follicular lymphoma, offering a potential respite from disease progression.

Polivy (Polatuzumab Vedotin-piiq) Efficacy in Treating Lymphoma

Polivy (polatuzumab vedotin-piiq) is an antibody-drug conjugate approved for use in combination with bendamustine and a rituximab product to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. The drug targets CD79b, a protein expressed in the majority of B-cells, and delivers a cytotoxic agent directly to these cells. The efficacy of Polivy was established in a randomized, controlled clinical trial that compared the Polivy combination regimen to bendamustine plus rituximab alone. The study demonstrated a significant improvement in complete response rates and overall survival among patients treated with Polivy.

In the clinical trial, the addition of Polivy to bendamustine and rituximab resulted in not only higher complete response rates but also an extension in progression-free survival (PFS) compared to the control group. This suggests that Polivy can substantially benefit patients with relapsed or refractory DLBCL, offering a chance for better disease control and potentially improved survival outcomes. However, it is important to note that Polivy is not indicated for patients with primary central nervous system lymphoma.